Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27997572 | 1.00 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29610258 | 0.87 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4959221 | 0.87 | GRM8 (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL496858 | 0.87 | GRM8 (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1529903 | 0.86 | SLC7A5 (0.34) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1537454 | 0.86 | ALOX15 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1537291 | 0.86 | ALOX15 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3402553 | 0.85 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL10636419 | 0.85 | GRM8 (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3402622 | 0.82 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190120855-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | THE CLEVELAND CLINIC FOUNDATION | 2019-04-25 | — | — | US | claimed |
| US-9977034-B2 | Biomarkers for fatty liver disease and methods using the same | Meabolon, Inc. (US) | 2018-05-22 | — | — | US | claimed |
| US-20150377910-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2015-12-31 | — | — | US | claimed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2546649-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20120122981-A1 | Biomarkers Related to Insulin Resistance and Methods using the Same | METABOLON, INC. | 2012-05-17 | — | — | US | claimed |
| EP-2414535-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | Metabolon Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| US-20100279956-A1 | Biomarkers For Fatty Liver Disease And Methods Using The Same | METABOLON, INC. | 2010-11-04 | — | — | US | claimed |
| WO-2010114897-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | GLAS USA LLC | 2025-01-02 | — | — | US | disclosed |
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | BIORA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-3321686-B1 | BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME | METABOLON INC (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4252629-A2 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | Biora Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3551046-B1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | BIORA THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-2414535-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | Metabolon Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114897-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| EP-2225386-A2 | PROCESS FOR THE ENZYMATIC PREPARATION OF A GAMMA-GLUTAMYL COMPOUND | Unilever PLC (GB) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009083454-A2 | PROCESS FOR THE ENZYMATIC PREPARATION OF A GAMMA-GLUTAMYL COMPOUND | UNILEVER PLC (GB) | 2009-07-09 | — | — | WO | disclosed |
| US-20090169704-A1 | Process for the enzymatic preparation of a gamma-glutamyl compound | CONOPCO, INC. D/B/A UNILEVER | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | FABP2, SI, MLNR | GABRP 3314/4885GABRD 2536/4885GABRA1 2930/4885 |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | FABP2, SI, MLNR | GABRP 3314/4885GABRD 2536/4885GABRA1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.